M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV

M Holdings Securities Inc. lifted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 68.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,979 shares of the company's stock after purchasing an additional 6,910 shares during the period. M Holdings Securities Inc.'s holdings in AbbVie were worth $3,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Several other institutional investors have also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the 2nd quarter worth approximately $25,000. TD Capital Management LLC raised its holdings in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the 2nd quarter valued at $36,000. Finally, Bear Mountain Capital Inc. lifted its holdings in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company's stock worth $40,000 after buying an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. Daiwa America upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Berenberg Bank upgraded AbbVie from a "hold" rating to a "buy" rating and increased their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. HSBC set a $225.00 price target on shares of AbbVie in a report on Thursday, October 2nd. BMO Capital Markets boosted their price objective on AbbVie from $215.00 to $240.00 and gave the company an "outperform" rating in a research report on Friday, September 12th. Finally, Raymond James Financial set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $241.85.

• Healthcare Rotation Underway: 3 Stocks Leading the Charge

Read Our Latest Stock Report on AbbVie

AbbVie Stock Performance

ABBV opened at $228.68 on Friday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The company has a market capitalization of $404.17 billion, a PE ratio of 173.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36. The business has a fifty day simple moving average of $228.19 and a 200 day simple moving average of $207.90. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

• ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 earnings per share. AbbVie's revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is currently 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read More

• Five stocks we like better than AbbVie
• 3 Best Fintech Stocks for a Portfolio Boost
• Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So
• What is an Earnings Surprise?
• The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
• Trading Stocks: RSI and Why it's Useful
• Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here